Earnings ·
Vogenx reports Q3 net loss of $0.47 per share as cash rises to $82.1M
VOGXVogenx, Inc.
Vogenx reported a third-quarter net loss of $4.9 million, or $0.47 per basic and diluted share, compared to a $284 thousand loss in the prior-year period. The increase was driven by $1.1 million in research and development expenses for the EMERGE Phase 2b study and expanded administrative headcount. Cash, cash equivalents, and marketable securities totaled $82.1 million as of September 30, 2026, bolstered by net proceeds from an August initial public offering that raised approximately $84.4 million. The company also announced the initiation of the EMERGE study for post-bariatric hypoglycemia and leadership changes including a new Chief Commercial Officer. Vogenx is a clinical-stage biopharmaceutical company developing novel therapeutics for metabolic and gastrointestinal diseases.